Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer , which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.72 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.88%.

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...

With its stock down 7.6% over the past three months, it is easy to disregard Pfizer (NYSE:PFE). We, however decided ...

Pfizer, however, reaffirmed its full-year forecast and announced measures to mitigate the impact of potential tariffs on ...